{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001684","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.579172+00:00","generated_at":"2026-06-27T05:26:07.093139+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kodiak Sciences: KSI-301 fails primary endpoint in wet AMD Phase 2b/3 trial","bullets":["Primary endpoint not met: KSI-301 failed to show non-inferior visual acuity gains vs aflibercept in wet AMD.","Cash and cash equivalents at Dec 31, 2021 were approximately $731.5M.","Pre-specified secondary analysis: 59% of KSI-301 patients achieved 5-month dosing with comparable visual acuity and anatomic improvements.","Safety: KSI-301 generally safe; intraocular inflammation in 3.2% vs 0% for aflibercept; all resolved.","Trial randomized 559 participants, ~80% in US; flexible long-interval regimen for KSI-301 vs fixed 2-month for aflibercept."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001684","json":"https://secwatch.observer/filing/0000950170-22-001684.json","markdown":"https://secwatch.observer/filing/0000950170-22-001684.md","text":"https://secwatch.observer/filing/0000950170-22-001684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022001684/0000950170-22-001684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022001684/kod-20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:26:07.093139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}